ArticlemAbs2026
P329G-engager: a universal mix & match antibody-based adaptor platform for cancer immunotherapy.
Article in mAbs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- DOTAM-TCB: Universal Small Molecule-guided Hapten- and T Cell-bispecific Antibodies for Cancer Immunotherapy.Antibody therapeutics · 2026Article
- T cell engagers in autoimmune diseases.Nature reviews. Immunology · 2026Review
- The trinity of T cell engagement: navigating the molecular and clinical landscape of CAR-T, TILs, and TCEs in the war against cancer.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Targeting various combinations of tumor antigens and immune cell receptors is of increasing importance in antibody-based cancer immunotherapy. Here, we present a novel modular P329G-engager platform that enables rapid combination of primary tumor-targeting and secondary immune effector antibodies. The platform utilizes two antibodies, each selected from: 1) a set of tumor-targeting adaptor antibodies, bearing P329G mutations in the Fc region, and 2) a set of P329G-targeting (bispecific) cell engagers, including innate and T cell engagers, costimulators and immunocytokines. Specifically, upon defining a tumor-associated cell surface target, a primary adaptor - tumor antigen-binding IgG1 antibody with Fc-silencing P329G L234A L235A mutations - is administered. Subsequently, a secondary antibody recognizing the P329G mutation is chosen from a panel of effector cell engagers with different modes of action - ADCC-competent P329G-innate cell engagers (P329G-ICE), P329G-T cell bispecifics (P329G-TCB), P329G-costimulators (P329G-CD28/4-1BBL), or P329G-immunocytokine (P329G-IL2v).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.